公开(公告)号：US20220079971A1

公开(公告)日：2022-03-17

申请号：US17422982

申请日：2020-01-16

Applicant: Genzyme Corporation

Inventor： Akin Akinc

IPC: A61K31/713 ,  C12N15/113 ,  A61K9/00 ,  A61K45/06 ,  A61K47/54

Abstract: The invention relates to pharmaceutical compositions comprising an iRNA agent, e.g., double stranded ribonucleic acid (dsRNA) agent and methods of using such compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).

公开(公告)号：US20220017902A1

公开(公告)日：2022-01-20

申请号：US17375785

申请日：2021-07-14

Applicant: Genzyme Corporation

Inventor： Akin Akinc ,  Benny Sorensen ,  Pushkal Garg ,  Gabriel Robbie

IPC: C12N15/113 ,  A61K31/713 ,  A61K47/54

Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.

公开(公告)号：US20210254063A1

公开(公告)日：2021-08-19

申请号：US17129761

申请日：2020-12-21

Applicant: Genzyme Corporation

Inventor： Akin Akinc ,  Alfica Sehgal ,  Ivanka Toudjarska ,  Donald Foster ,  Stuart Milstein ,  Brian Bettencourt ,  Martin A. Maier ,  Klaus Charisse ,  Satyanarayana Kuchimanchi ,  Kallanthottathil G. Rajeev ,  Muthiah Manoharan

IPC: C12N15/113 ,  A61K31/713

Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.

公开(公告)号：US20230365965A1

公开(公告)日：2023-11-16

申请号：US18155655

申请日：2023-01-17

Applicant: Genzyme Corporation

Inventor： Akin Akinc ,  Alfica Sehgal ,  Ivanka Toudjarska ,  Donald Foster ,  Stuart Milstein ,  Brian Bettencourt ,  Martin A. Maier ,  Klaus Charisse ,  Satyanarayana Kuchimanchi ,  Kallanthottathil G. Rajeev ,  Muthiah Manoharan

IPC: C12N15/113 ,  A61K31/713

CPC classification number: C12N15/113 ,  A61K31/713 ,  C12N2310/14 ,  C12N2310/315 ,  C12N2310/321 ,  C12N2310/322 ,  C12N2310/335 ,  C12N2310/3515 ,  C12N2310/351 ,  C12N2320/30 ,  C12N2310/3521 ,  C12N2310/3533

Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.

公开(公告)号：US11091759B2

公开(公告)日：2021-08-17

申请号：US15371300

申请日：2016-12-07

Applicant: Genzyme Corporation

Inventor： Akin Akinc ,  Benny Sorensen ,  Pushkal Garg ,  Gabriel Robbie

IPC: C12N15/11 ,  C12N15/113 ,  A61K31/713 ,  A61K47/54

Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and to treat subjects having a Serpinc1-associated disease, e.g., a bleeding disorder, such as a hemophilia.

公开(公告)号：US20200216844A1

公开(公告)日：2020-07-09

申请号：US16220157

申请日：2018-12-14

Applicant: Genzyme Corporation

Inventor： Akin Akinc ,  Alfica Sehgal ,  Ivanka Toudjarska ,  Donald Foster ,  Stuart Milstein ,  Brian Bettencourt ,  Martin A. Maier ,  Klaus Charisse ,  Satyanarayana Kuchimanchi ,  Kallanthottathil G. Rajeev ,  Muthiah Manoharan

IPC: C12N15/113 ,  A61K31/713

Abstract: The invention relates to iRNA, e.g., double-stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to inhibit expression of Serpinc1 and methods of treating subjects having a bleeding disorder, such as a hemophilia.

公开(公告)号：US20230158058A1

公开(公告)日：2023-05-25

申请号：US17878884

申请日：2022-08-01

Applicant: Genzyme Corporation

Inventor： Akin Akinc

IPC: A61K31/7088 ,  A61P7/04

CPC classification number: A61K31/7088 ,  A61P7/04

Abstract: The invention relates to iRNA, e.g., double stranded ribonucleic acid (dsRNA), compositions targeting the Serpinc1 gene, and methods of using such iRNA, e.g., dsRNA, compositions to treat a bleeding event in a subject having a hemophilia (e.g., with or without inhibitors).